Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqGM - Nasdaq Real Time Price USD

HCW Biologics Inc. (HCWB)

Compare
0.2809
-0.0012
(-0.43%)
At close: April 1 at 4:00:02 PM EDT
0.2712
-0.01
(-3.45%)
After hours: April 1 at 7:59:43 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
2,566.7920
2,566.7920
2,841.7940
6,722.0900
--
Cost of Revenue
1,607.3890
1,607.3890
2,281.4340
4,135.7120
--
Gross Profit
959.4030
959.4030
560.3600
2,586.3780
--
Operating Expense
14,001.2860
14,001.2860
19,705.8310
17,665.1560
13,367.8340
Operating Income
-13,041.8830
-13,041.8830
-19,145.4710
-15,078.7780
-13,367.8340
Net Non Operating Interest Income Expense
-1,158.4410
-1,158.4410
-283.0420
-126.6600
--
Other Income Expense
-15,823.4900
-15,823.4900
-5,565.7640
304.7350
505.3660
Pretax Income
-30,023.8140
-30,023.8140
-24,994.2770
-14,900.7030
-12,862.4680
Net Income Common Stockholders
-30,023.8140
-30,023.8140
-24,994.2770
-14,900.7030
-12,862.4680
Diluted NI Available to Com Stockholders
-30,023.8140
-30,023.8140
-24,994.2770
-14,900.7030
-12,862.4680
Basic EPS
-1.01
-0.77
-0.70
-0.42
-0.69
Diluted EPS
-1.01
-0.77
-0.70
-0.42
-0.69
Basic Average Shares
37,216.6980
38,793.0180
35,929.4460
35,822.2490
18,770.9350
Diluted Average Shares
37,216.6980
38,793.0180
35,929.4460
35,822.2490
18,770.9350
Total Operating Income as Reported
-29,479.6670
-29,479.6670
-25,717.1600
-15,078.7780
-13,367.8340
Rent Expense Supplemental
205.5110
205.5110
156.8070
132.7390
100.4570
Total Expenses
15,608.6750
15,608.6750
21,987.2650
21,800.8680
13,367.8340
Net Income from Continuing & Discontinued Operation
-30,023.8140
-30,023.8140
-24,994.2770
-14,900.7030
-12,862.4680
Normalized Income
-14,113.3340
-14,113.3340
-18,422.5880
-14,900.7030
-12,862.4680
Interest Income
--
--
--
--
505.3660
Interest Expense
1,158.4410
1,158.4410
283.0420
126.6600
--
Net Interest Income
-1,158.4410
-1,158.4410
-283.0420
-126.6600
--
EBIT
-28,865.3730
-28,865.3730
-24,711.2350
-14,774.0430
-12,862.4680
EBITDA
-27,680.9840
-27,680.9840
-23,576.0510
-14,056.1890
-12,318.8700
Reconciled Cost of Revenue
700.5540
700.5540
1,413.0130
3,756.3160
--
Reconciled Depreciation
1,184.3890
1,184.3890
1,135.1840
717.8540
543.5980
Net Income from Continuing Operation Net Minority Interest
-30,023.8140
-30,023.8140
-24,994.2770
-14,900.7030
-12,862.4680
Total Unusual Items Excluding Goodwill
-15,910.4800
-15,910.4800
-6,571.6890
--
--
Total Unusual Items
-15,910.4800
-15,910.4800
-6,571.6890
--
--
Normalized EBITDA
-11,770.5040
-11,770.5040
-17,004.3620
-14,056.1890
-12,318.8700
12/31/2021 - 7/20/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ERNA Ernexa Therapeutics Inc.
0.1849
+3.88%
 
SXTP 60 Degrees Pharmaceuticals, Inc.
1.8900
+5.00%
 
OGEN Oragenics, Inc.
0.2123
+1.10%
 
GLYC GlycoMimetics, Inc.
0.2011
-4.24%
 
TSBX Turnstone Biologics Corp.
0.3760
-8.29%
 
CLYM Climb Bio, Inc.
1.2000
-1.64%
 
MBIO Mustang Bio, Inc.
1.2931
+3.45%
 
LYRA Lyra Therapeutics, Inc.
0.1201
-4.91%
 
APLM Apollomics, Inc.
7.00
+12.90%
 
APM Aptorum Group Limited
0.8594
+2.31%